Current Report Filing (8-k)
August 21 2019 - 5:28PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
August 18, 2019
ORAMED
PHARMACEUTICALS INC.
|
(Exact
name of registrant as specified in its charter)
|
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1185
Avenue of the Americas, Suite 228, New York, New York
|
|
10036
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
844-967-2633
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.012
|
|
ORMP
|
|
The Nasdaq Capital Market, Tel Aviv Stock Exchange
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On August 5, 2019,
Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Joshua Hexter, to serve as Chief Operating & Business
Officer, effective September 19, 2019.
Prior to his appointment,
Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (NASDAQ/TASE: BWAY) from 2018 to 2019, commercial stage medical
device company focused on the development and sale of non-invasive neuromodulation products. From 2013 to 2018, Mr. Hexter served
as Chief Operating Officer and VP Business Development of the Company and from 2007 to 2013, Mr. Hexter was a Director or Executive
Director of BioLineRx Ltd. (NASDAQ/TASE: BLRX), a biopharmaceutical development company dedicated to identifying, in-licensing
and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was a member of the board
of directors and Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market-driven biosensors. Mr.
Hexter holds a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston
University.
Mr. Hexter will be
employed by the Company pursuant to an employment agreement with the Company’s wholly-owned Israeli subsidiary, Oramed Ltd.
Mr. Hexter's gross monthly salary will be NIS 56,000, and he will be provided with a company car. Mr. Hexter will be eligible for
bonuses and equity grants in amounts to be determined at the discretion of the Company’s Board of Directors and the Compensation
Committee of the Company’s Board of Directors, as applicable. In connection with Mr. Hexter’s appointment, the Company
expects to enter into its standard indemnification agreement with Mr. Hexter, on substantially the same terms as the indemnification
agreements previously entered into between the Company and each of its directors and executive officers. Other than having previously
been an officer of, and subsequently a consultant to, the Company, Mr. Hexter is not a party to any transactions that are disclosable
under Item 404 of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
Name:
|
Nadav
Kidron
|
|
Title:
|
President
and CEO
|
August 18, 2019
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Sep 2023 to Sep 2024